# AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

Study · id `cardio:ct-nct07697391` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07697391](<https://clinicaltrials.gov/study/NCT07697391>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07697391

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 285 participants.

## Technical summary

Registry record NCT07697391. Randomized; no masking; primary purpose treatment. Start 2026-07-16 (actual); primary completion 2027-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 285 participants (planned count; ClinicalTrials.gov record NCT07697391, source copy `cardio:ctgov-nct07697391-2026-11-04`, retrieved 2026-11-18)
- Started: 2026-07-16 (actual) (ClinicalTrials.gov record NCT07697391, source copy `cardio:ctgov-nct07697391-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2027-10-31 (anticipated) (ClinicalTrials.gov record NCT07697391, source copy `cardio:ctgov-nct07697391-2026-11-04`, retrieved 2026-11-18)
- Completion: 2028-01-31 (anticipated) (ClinicalTrials.gov record NCT07697391, source copy `cardio:ctgov-nct07697391-2026-11-04`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07697391, source copy `cardio:ctgov-nct07697391-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07697391-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes
- Acronym: AI-LIFE-T2D-OB
- Condition: Obesity
- Condition: Diabetes Mellitus, Type 2
- Intervention (Behavioral): AI-Assisted Intensive Lifestyle Intervention
- Intervention (Drug): Tirzepatide
- Intervention (Behavioral): Standard Lifestyle Management
- Lead sponsor: The First Affiliated Hospital of Anhui Medical University
- Lead sponsor class: OTHER
- Collaborator: Zhejiang Nutriease Health Technology Co. Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital of Anhui Medical University (`cardio:org-the-first-affiliated-hospital-of-anhui-medical-university`)

## Provenance

Content hash: 28690fdd0fe34b6fff60a9ae14e0883e018ab23cb85a27ef049460608d26144f
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
